iwAL 2018 | Future frontiers in AML: the five key therapy pillars & the future of trials

Naval Daver

Acute myeloid leukemia (AML) is experiencing a therapy boom, with increasing numbers of novel treatments being approved and more in the pipeline, for both frontline and salvage therapy. Here, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, explains his viewpoint on the five main therapy ‘pillars’ being focused on for AML, discussing the current situation for each type, including the successes and concerns to consider. The interview is rounded up by Dr Daver giving an insightful perspective into this new frontier, where there are many possible combinations and clinical trials will need to be designed to reflect this. He gives the example of an upcoming trial that he is the principal investigator of, which has seven arms testing different combinations within smaller cohorts (NCT03390296).

Share this video